,address1,address2,city,state,zip,country,phone,fax,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,177 East Colorado Boulevard,Suite 700,Pasadena,CA,91105,United States,626 304 3400,626 304 3401,https://arrowheadpharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",397,"{'maxAge': 1, 'name': 'Dr. Christopher R. Anzalone Ph.D.', 'age': 53, 'title': 'CEO, Pres & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 1649420, 'exercisedValue': 996462, 'unexercisedValue': 14937168}",9,8,3,1,4,1693526400,1672444800,86400,2,30.54,30.59,28.88,30.73,30.54,30.59,28.88,30.73,0.0,0.99343,-10.4404335,1798363,1798363,916140,1065460,1065460,28.71,29.37,1300,1000,3100021504,23.09,42.48,12.099392,31.1026,32.6459,0.0,0.0,USD,3011268608,-0.70685995,103938525,107193000,6333995,5571437,1690761600,1693440000,0.0591,0.0496,0.70739996,7.16,0.0705,107193000,3.406,8.490899,1664496000,1696032000,1688083200,-181107008,-1.62,-2.77,-2.76,1:10,1321488000,11.753,-17.796,-0.15685129,0.14113986,NMS,EQUITY,ARWR,ARWR,"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc.",756052200,America/New_York,EDT,c1090240-5c7b-33ae-b362-c474642e552e,finmb_203142,-14400000,28.92,90.0,27.0,58.54,60.0,2.1,buy,13,451703008,4.214,-169208000,345798016,6.45,6.695,256212992,90.526,2.408,-0.14579001,-0.4303,243231000,-226575744,-197370000,-0.512,1.0,-0.66042,-0.70449996,USD,
1,177 East Colorado Boulevard,Suite 700,Pasadena,CA,91105,United States,626 304 3400,626 304 3401,https://arrowheadpharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",397,"{'maxAge': 1, 'name': 'Mr. Kenneth A. Myszkowski', 'age': 56, 'title': 'Chief Financial Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 761552, 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,3,1,4,1693526400,1672444800,86400,2,30.54,30.59,28.88,30.73,30.54,30.59,28.88,30.73,0.0,0.99343,-10.4404335,1798363,1798363,916140,1065460,1065460,28.71,29.37,1300,1000,3100021504,23.09,42.48,12.099392,31.1026,32.6459,0.0,0.0,USD,3011268608,-0.70685995,103938525,107193000,6333995,5571437,1690761600,1693440000,0.0591,0.0496,0.70739996,7.16,0.0705,107193000,3.406,8.490899,1664496000,1696032000,1688083200,-181107008,-1.62,-2.77,-2.76,1:10,1321488000,11.753,-17.796,-0.15685129,0.14113986,NMS,EQUITY,ARWR,ARWR,"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc.",756052200,America/New_York,EDT,c1090240-5c7b-33ae-b362-c474642e552e,finmb_203142,-14400000,28.92,90.0,27.0,58.54,60.0,2.1,buy,13,451703008,4.214,-169208000,345798016,6.45,6.695,256212992,90.526,2.408,-0.14579001,-0.4303,243231000,-226575744,-197370000,-0.512,1.0,-0.66042,-0.70449996,USD,
2,177 East Colorado Boulevard,Suite 700,Pasadena,CA,91105,United States,626 304 3400,626 304 3401,https://arrowheadpharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",397,"{'maxAge': 1, 'name': ""Mr. Patrick  O'Brien J.D., PharmD"", 'age': 58, 'title': 'COO, Gen. Counsel & Sec.', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 749863, 'exercisedValue': 172200, 'unexercisedValue': 0}",9,8,3,1,4,1693526400,1672444800,86400,2,30.54,30.59,28.88,30.73,30.54,30.59,28.88,30.73,0.0,0.99343,-10.4404335,1798363,1798363,916140,1065460,1065460,28.71,29.37,1300,1000,3100021504,23.09,42.48,12.099392,31.1026,32.6459,0.0,0.0,USD,3011268608,-0.70685995,103938525,107193000,6333995,5571437,1690761600,1693440000,0.0591,0.0496,0.70739996,7.16,0.0705,107193000,3.406,8.490899,1664496000,1696032000,1688083200,-181107008,-1.62,-2.77,-2.76,1:10,1321488000,11.753,-17.796,-0.15685129,0.14113986,NMS,EQUITY,ARWR,ARWR,"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc.",756052200,America/New_York,EDT,c1090240-5c7b-33ae-b362-c474642e552e,finmb_203142,-14400000,28.92,90.0,27.0,58.54,60.0,2.1,buy,13,451703008,4.214,-169208000,345798016,6.45,6.695,256212992,90.526,2.408,-0.14579001,-0.4303,243231000,-226575744,-197370000,-0.512,1.0,-0.66042,-0.70449996,USD,
3,177 East Colorado Boulevard,Suite 700,Pasadena,CA,91105,United States,626 304 3400,626 304 3401,https://arrowheadpharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",397,"{'maxAge': 1, 'name': 'Dr. James C. Hamilton M.D., MBA', 'age': 44, 'title': 'Chief of Discovery & Translational Medicine', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 676814, 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,3,1,4,1693526400,1672444800,86400,2,30.54,30.59,28.88,30.73,30.54,30.59,28.88,30.73,0.0,0.99343,-10.4404335,1798363,1798363,916140,1065460,1065460,28.71,29.37,1300,1000,3100021504,23.09,42.48,12.099392,31.1026,32.6459,0.0,0.0,USD,3011268608,-0.70685995,103938525,107193000,6333995,5571437,1690761600,1693440000,0.0591,0.0496,0.70739996,7.16,0.0705,107193000,3.406,8.490899,1664496000,1696032000,1688083200,-181107008,-1.62,-2.77,-2.76,1:10,1321488000,11.753,-17.796,-0.15685129,0.14113986,NMS,EQUITY,ARWR,ARWR,"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc.",756052200,America/New_York,EDT,c1090240-5c7b-33ae-b362-c474642e552e,finmb_203142,-14400000,28.92,90.0,27.0,58.54,60.0,2.1,buy,13,451703008,4.214,-169208000,345798016,6.45,6.695,256212992,90.526,2.408,-0.14579001,-0.4303,243231000,-226575744,-197370000,-0.512,1.0,-0.66042,-0.70449996,USD,
4,177 East Colorado Boulevard,Suite 700,Pasadena,CA,91105,United States,626 304 3400,626 304 3401,https://arrowheadpharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",397,"{'maxAge': 1, 'name': 'Ms. Tracie  Oliver', 'title': 'Chief Commercial Officer', 'fiscalYear': 2022, 'totalPay': 449579, 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,3,1,4,1693526400,1672444800,86400,2,30.54,30.59,28.88,30.73,30.54,30.59,28.88,30.73,0.0,0.99343,-10.4404335,1798363,1798363,916140,1065460,1065460,28.71,29.37,1300,1000,3100021504,23.09,42.48,12.099392,31.1026,32.6459,0.0,0.0,USD,3011268608,-0.70685995,103938525,107193000,6333995,5571437,1690761600,1693440000,0.0591,0.0496,0.70739996,7.16,0.0705,107193000,3.406,8.490899,1664496000,1696032000,1688083200,-181107008,-1.62,-2.77,-2.76,1:10,1321488000,11.753,-17.796,-0.15685129,0.14113986,NMS,EQUITY,ARWR,ARWR,"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc.",756052200,America/New_York,EDT,c1090240-5c7b-33ae-b362-c474642e552e,finmb_203142,-14400000,28.92,90.0,27.0,58.54,60.0,2.1,buy,13,451703008,4.214,-169208000,345798016,6.45,6.695,256212992,90.526,2.408,-0.14579001,-0.4303,243231000,-226575744,-197370000,-0.512,1.0,-0.66042,-0.70449996,USD,
5,177 East Colorado Boulevard,Suite 700,Pasadena,CA,91105,United States,626 304 3400,626 304 3401,https://arrowheadpharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",397,"{'maxAge': 1, 'name': 'Dr. Mark M. Davis Ph.D.', 'title': 'Founder and Founder & Director of Insert Therapeutics Inc & Calando', 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,3,1,4,1693526400,1672444800,86400,2,30.54,30.59,28.88,30.73,30.54,30.59,28.88,30.73,0.0,0.99343,-10.4404335,1798363,1798363,916140,1065460,1065460,28.71,29.37,1300,1000,3100021504,23.09,42.48,12.099392,31.1026,32.6459,0.0,0.0,USD,3011268608,-0.70685995,103938525,107193000,6333995,5571437,1690761600,1693440000,0.0591,0.0496,0.70739996,7.16,0.0705,107193000,3.406,8.490899,1664496000,1696032000,1688083200,-181107008,-1.62,-2.77,-2.76,1:10,1321488000,11.753,-17.796,-0.15685129,0.14113986,NMS,EQUITY,ARWR,ARWR,"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc.",756052200,America/New_York,EDT,c1090240-5c7b-33ae-b362-c474642e552e,finmb_203142,-14400000,28.92,90.0,27.0,58.54,60.0,2.1,buy,13,451703008,4.214,-169208000,345798016,6.45,6.695,256212992,90.526,2.408,-0.14579001,-0.4303,243231000,-226575744,-197370000,-0.512,1.0,-0.66042,-0.70449996,USD,
6,177 East Colorado Boulevard,Suite 700,Pasadena,CA,91105,United States,626 304 3400,626 304 3401,https://arrowheadpharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",397,"{'maxAge': 1, 'name': 'Dr. Vincent  Anzalone CFA', 'title': 'Head of Investor Relations & VP', 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,3,1,4,1693526400,1672444800,86400,2,30.54,30.59,28.88,30.73,30.54,30.59,28.88,30.73,0.0,0.99343,-10.4404335,1798363,1798363,916140,1065460,1065460,28.71,29.37,1300,1000,3100021504,23.09,42.48,12.099392,31.1026,32.6459,0.0,0.0,USD,3011268608,-0.70685995,103938525,107193000,6333995,5571437,1690761600,1693440000,0.0591,0.0496,0.70739996,7.16,0.0705,107193000,3.406,8.490899,1664496000,1696032000,1688083200,-181107008,-1.62,-2.77,-2.76,1:10,1321488000,11.753,-17.796,-0.15685129,0.14113986,NMS,EQUITY,ARWR,ARWR,"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc.",756052200,America/New_York,EDT,c1090240-5c7b-33ae-b362-c474642e552e,finmb_203142,-14400000,28.92,90.0,27.0,58.54,60.0,2.1,buy,13,451703008,4.214,-169208000,345798016,6.45,6.695,256212992,90.526,2.408,-0.14579001,-0.4303,243231000,-226575744,-197370000,-0.512,1.0,-0.66042,-0.70449996,USD,
7,177 East Colorado Boulevard,Suite 700,Pasadena,CA,91105,United States,626 304 3400,626 304 3401,https://arrowheadpharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",397,"{'maxAge': 1, 'name': 'Mr. Howard  Lovy', 'title': 'Director of Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,3,1,4,1693526400,1672444800,86400,2,30.54,30.59,28.88,30.73,30.54,30.59,28.88,30.73,0.0,0.99343,-10.4404335,1798363,1798363,916140,1065460,1065460,28.71,29.37,1300,1000,3100021504,23.09,42.48,12.099392,31.1026,32.6459,0.0,0.0,USD,3011268608,-0.70685995,103938525,107193000,6333995,5571437,1690761600,1693440000,0.0591,0.0496,0.70739996,7.16,0.0705,107193000,3.406,8.490899,1664496000,1696032000,1688083200,-181107008,-1.62,-2.77,-2.76,1:10,1321488000,11.753,-17.796,-0.15685129,0.14113986,NMS,EQUITY,ARWR,ARWR,"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc.",756052200,America/New_York,EDT,c1090240-5c7b-33ae-b362-c474642e552e,finmb_203142,-14400000,28.92,90.0,27.0,58.54,60.0,2.1,buy,13,451703008,4.214,-169208000,345798016,6.45,6.695,256212992,90.526,2.408,-0.14579001,-0.4303,243231000,-226575744,-197370000,-0.512,1.0,-0.66042,-0.70449996,USD,
8,177 East Colorado Boulevard,Suite 700,Pasadena,CA,91105,United States,626 304 3400,626 304 3401,https://arrowheadpharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",397,"{'maxAge': 1, 'name': 'Dr. Mark  Seefeld', 'age': 68, 'title': 'Head of Toxicology & VP', 'yearBorn': 1954, 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,3,1,4,1693526400,1672444800,86400,2,30.54,30.59,28.88,30.73,30.54,30.59,28.88,30.73,0.0,0.99343,-10.4404335,1798363,1798363,916140,1065460,1065460,28.71,29.37,1300,1000,3100021504,23.09,42.48,12.099392,31.1026,32.6459,0.0,0.0,USD,3011268608,-0.70685995,103938525,107193000,6333995,5571437,1690761600,1693440000,0.0591,0.0496,0.70739996,7.16,0.0705,107193000,3.406,8.490899,1664496000,1696032000,1688083200,-181107008,-1.62,-2.77,-2.76,1:10,1321488000,11.753,-17.796,-0.15685129,0.14113986,NMS,EQUITY,ARWR,ARWR,"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc.",756052200,America/New_York,EDT,c1090240-5c7b-33ae-b362-c474642e552e,finmb_203142,-14400000,28.92,90.0,27.0,58.54,60.0,2.1,buy,13,451703008,4.214,-169208000,345798016,6.45,6.695,256212992,90.526,2.408,-0.14579001,-0.4303,243231000,-226575744,-197370000,-0.512,1.0,-0.66042,-0.70449996,USD,
9,177 East Colorado Boulevard,Suite 700,Pasadena,CA,91105,United States,626 304 3400,626 304 3401,https://arrowheadpharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.",397,"{'maxAge': 1, 'name': 'Dr. Javier  San Martin M.D.', 'age': 57, 'title': 'Chief Medical Officer', 'yearBorn': 1965, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,3,1,4,1693526400,1672444800,86400,2,30.54,30.59,28.88,30.73,30.54,30.59,28.88,30.73,0.0,0.99343,-10.4404335,1798363,1798363,916140,1065460,1065460,28.71,29.37,1300,1000,3100021504,23.09,42.48,12.099392,31.1026,32.6459,0.0,0.0,USD,3011268608,-0.70685995,103938525,107193000,6333995,5571437,1690761600,1693440000,0.0591,0.0496,0.70739996,7.16,0.0705,107193000,3.406,8.490899,1664496000,1696032000,1688083200,-181107008,-1.62,-2.77,-2.76,1:10,1321488000,11.753,-17.796,-0.15685129,0.14113986,NMS,EQUITY,ARWR,ARWR,"Arrowhead Pharmaceuticals, Inc.","Arrowhead Pharmaceuticals, Inc.",756052200,America/New_York,EDT,c1090240-5c7b-33ae-b362-c474642e552e,finmb_203142,-14400000,28.92,90.0,27.0,58.54,60.0,2.1,buy,13,451703008,4.214,-169208000,345798016,6.45,6.695,256212992,90.526,2.408,-0.14579001,-0.4303,243231000,-226575744,-197370000,-0.512,1.0,-0.66042,-0.70449996,USD,
